The Indian pharmaceutical industry has emerged as a major player in the global healthcare landscape, thanks to its innovative capabilities, low-cost manufacturing, and ability to cater to a diverse range of markets. India's pharmaceutical industry is the world's third-largest in terms of volume, and it accounts for more than 20% of the global supply of generic drugs.

The Indian pharma industry's growth can be attributed to several factors, including a strong focus on research and development, investment in state-of-the-art manufacturing facilities, and a favorable regulatory environment. The industry has been able to leverage these advantages to develop a broad range of medicines, including critical drugs for diseases like HIV/AIDS, tuberculosis, and malaria.

One of the most significant contributions of the Indian pharma industry has been its role in providing low-cost generic drugs to developing countries. India's generic drugs are of high quality and are often available at a fraction of the cost of their branded counterparts. This has made life-saving medications accessible to millions of people in developing countries who would otherwise not be able to afford them.

For instance, India has been a major supplier of antiretroviral drugs used in the treatment of HIV/AIDS. The country's 
 pharma franchise company have been able to manufacture these drugs at a much lower cost than their Western counterparts, making them affordable to people in developing countries. Similarly, India has played a critical role in providing low-cost drugs for the treatment of tuberculosis, which is a major public health challenge in many developing countries.

In addition to providing low-cost drugs, the Indian pharma industry has also been instrumental in developing new drugs for a wide range of diseases. The industry's focus on research and development has led to several breakthroughs in the development of drugs for diseases like cancer, diabetes, and cardiovascular disorders.

The vaccine, called Covaxin, was developed in collaboration with the Indian Council of Medical Research (ICMR) and has been granted emergency use authorization by the Indian government. The vaccine has been a game-changer in India's fight against the COVID-19 pandemic, and it is now being exported to several countries.

The drug business in India is on the way to consistent development, explicit variables and motivators will empower it to accomplish its aggressive vision of coming to $130 billion by 2030. Expanded Research and development speculations are the need of great importance which can be supported through boost by the send off of duty motivations as well as the reception of additional adaptable administrative standards around clinical preliminaries. Additionally, the public authority ought to effectively utilize the current Programming interface units. The significant driving variables for developing the homegrown market in the nation can be ascribed to the higher weight of illnesses. The neighborhood creation of APIs is boosted by the quickly developing populace of the country. This gives roads to drug organizations to take care of the homegrown market as well as enter worldwide business sectors with relatively higher age gatherings. To construct a supportable market and keep a vigorous development rate, imaginative plans of action ought to be created for balance in drug value control and neighborhood producing costs.

Despite these contributions, the Indian pharma industry faces several challenges. One of the most significant challenges is the need to improve its regulatory environment to ensure that quality standards are maintained across the industry. There have been several instances of sub-standard drugs being sold by 
Indian pharma companies, which have led to concerns about the safety and efficacy of drugs produced in India